If you’ve ever known someone with cancer, you know the terrible side effects of the disease… mutated cells replicating throughout the body, slowly taking over vital organs, until they stop functioning.

Traditional medicine techniques for fighting cancer usually include cutting out the mutated cancer cells, or attempting to kill them off through highly toxic chemotherapy or radiotherapy.

Some advanced-stage cancer patients even make the choice to just forego the misery of treatment, attempting to maintain a little quality of life before succumbing to the disease.

Scientists at the Mayo Clinic in Florida hope to change that by exploring treatment options that focus on the molecular DNA level. Already, they’ve identified the microprocessor inside cells that control its growth.

Researchers believe that if they can regulate the mechanism that controls growth in cells, called microRNA, they should be able to directly target the growth of cancer cells, stopping them in their tracks.

The body regulates the growth of cells by having microRNA produce a protein called PLEKHA7. This protein breaks the cell bonds and stops growth. In cancer cells there are deficiencies in microRNA, which is what causes them to replicate non-stop.

Scientists found that they were able to reverse the growth process in cancer tumors with injections containing microRNA and the PLEKHA7 protein.

Department of Cancer Biology professor Panos Anastasiadis stated that this experimental treatment has been performed with promising results in, “very aggressive human cell lines from breast and bladder cancer.”

Currently the timeline for mass production of this treatment is unclear, however the results are looking like a very viable alternative to existing treatment options. With innovation at all-time highs within the biotech industry, look forward to continued breakthroughs in the fight against cancer.

Ben Benoy

Ben Benoy
Editor, BioTech Intel Trader

How to Prep Your Retirement Savings for 2020

“This is no longer a question of ‘if’ but simply a question of ‘when.’” Harry Dent opens up about his latest forecast for 2020 and how a number of factors could lead… Read More>>
Ben Benoy
Ben Benoy is a veteran of the U.S. Marine Corps and has been an active retail trader since 2006. He identifies investment opportunities based on key social media trends. He first identified the concept in 2008 and has since developed a tool for tracking investment “chatter” between social media users. His proprietary Social Media Stock Sentiment system has developed into a state-of-the-art platform that identifies and classifies chatter about stocks through algorithms and other indicators to forecast stock-price direction. Ben’s track record speaks for itself — over the past 12 months, his system boasts a win rate of 82.2% on 112 stock trades.